Korean Biotech Roundup: String Of Positive R&D Developments Outweighs Some Setbacks

The hopes of spring may be returning to the South Korean biotech industry after a series of encouraging developments in recent months has more than made up for some other disappointing news, with progress in original R&D activities notable across the board.

Among the major positives, an independent data monitoring committee (IDMC) has recommended the continuation of a Phase IIa trial for Bridge Biotherapeutics, Inc.’s idiopathic pulmonary fibrosis therapy, while